Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide

Phase 2 Completed 730 enrolled Pfizer

RandomizedParallel-groupQuadruple-blindTreatment

Summary

PH-797804 is an oral anti-inflammatory drug that may reduce the inflammation that is associated with Chronic Obstructive Pulmonary Disease (COPD). PH-797804 will be dosed to patients with Chronic Obstructive Pulmonary Disease (COPD) to evaluate its potential safety and efficacy profile in Chronic Obstructive Pulmonary Disease (COPD)

Timeline

Start: 2012-04
Primary completion: 2013-09
Completion: 2013-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PH-797804	Small molecule	0.25 mg	Oral
Subject	PH-797804	Small molecule	1 mg	Oral
Subject	PH-797804	Small molecule	3 mg	Oral
Subject	PH-797804	Small molecule	6 mg	Oral
Subject	PH-797804	Small molecule	10 mg	Oral
Background	Tiotropium	Other / unclassified	18 ug	—

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide

Summary

Timeline

Drugs

Indications